Foreign And Domestic Firms See Eye-To-Eye In China’s Latest Innovation Proposal
This article was originally published in PharmAsia News
Executive Summary
Multinationals and domestic pharma companies in China are joining forces to demand an innovation-enabling environment, underscored by faster regulatory reform, better market access and stronger intellectual property protection.